Skip to search formSkip to main contentSkip to account menu

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Neuroblastoma (NBL) is an aggressive malignancy of the sympathetic nervous system (NS). Advanced stage neuroblastomas prove fatal… 
2014
2014
Purpose Tumor-specific monoclonal antibodies (mAb) are a common type of immunotherapy capable of engaging innate immune cells to… 
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Introduction: Hu14.18-IL2 (APN301, Apeiron… 
2010
2010
Response to immunocytokine (IC) therapy is dependent on natural killer (NK) cells in murine neuroblastoma (NBL) models… 
2010
2010
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore… 
Review
2008
Review
2008
3002 Background: The hu14.18-IL2 fusion protein consists of IL2 linked to a humanized mAb that recognizes the GD2… 
2008
2008
9039 Background: The hu14.18-IL2 immunocytokine consists of a humanized anti-GD2 monoclonal antibody linked to IL2. It has potent… 
2001
2001
Immuntherapie von Krebs hat eine lange Geschichte. Die bisher erfolgreichsten Ansätze beruhen auf Antikörpern (AK) mit einer…